Nov 1, 2021
David Nutt is a psychiatrist and a
neuroscientist at Downing College, Cambridge. His
research focuses on illicit drugs—their harm, classification, and
potential for therapeutic use in psychiatry. In this episode, David
discusses his framework for assessing the potential harm caused by
common recreational drugs and explains how they are regulated,
which is oftentimes misaligned with actual risk. He describes in
detail the neurobiology, mechanisms of action, and addiction
potential of alcohol, opiates, cocaine, and methamphetamine and
contrasts those with psychedelics, which have been given a similar
regulatory classification despite their relatively low risk of harm
and their numerous potential therapeutic uses. Additionally, David
explains the promise of psychedelics like ketamine, MDMA, and
psilocybin for treating drug addiction and depression and discusses
how political pressures have created roadblocks to future necessary
research.
We
discuss: